Leukemic transformation in patients with myelodysplastic syndromes after treatment with granulocyte colony-stimulating factor

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Leukemia and Lymphoma

• Publication date

  2012-02-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2012.668679PMID 22360720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Myelodysplastic Syndromes

  2013cited by this paper
• G-CSF and its receptor in myeloid malignancy.

  2010cited by this paper
• Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy

  2010cited by this paper
• Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.

  2008cited by this paper
• Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

  2008cited by this paper
• Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

  2008cited by this paper
• Response: G-CSF and aplastic anemia

  2007cited by this paper
• Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT).

  2007cited by this paper
• Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes

  2007cited by this paper
• Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.

  2005cited by this paper
• Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

  2005cited by this paper
• A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

  2003cited by this paper
• Hematopoietic growth factors in myelodysplastic syndromes.

  2003cited by this paper
• Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients

  2002cited by this paper
• Myelodysplasia.

  1999cited by this paper
• Immunologic selection of hemopoietic precursor cells utilizing antibody-mediated plate binding ("panning").

  1985cited by this paper

• aplastic anemia that can be sustained on discontinuation of drug Eltrombopag restores trilineage hematopoiesis in refractory severe

  2014influential citation
• Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

  2014influential citation